6505--Pharmacy Amtagvi

Awarded Limited / Sole Source Justification Posted

Solicitation number
36C24826N0268
Agency
Set-aside
No set-aside

Opportunity facts

Contract number
36F79724D0206-36C24826N0268 Federal contract award

Notice details come from SAM.gov. Updated .

About this opportunity

The Department of Veterans Affairs Veterans Integrated Service Network 8 issued a Limited/Sole Source Justification Notice for a delivery order to procure Amtagvi (Lifileucel), an FDA-approved tumor-infiltrating lymphocyte (TIL) therapy for cancer treatment. The justification for the sole source procurement is based on Amtagvi being the only FDA-approved TIL therapy currently available, developed exclusively by Iovance Biotherapeutics Manufacturing LLC, with no clinically equivalent alternatives in the marketplace. The VA awarded the contract to Iovance Biotherapeutics Manufacturing LLC, the sole contractor capable of supplying this specialized pharmaceutical product. The estimated contract value is $393,365.83, with a performance period running from January 5, 2026 through April 4, 2026. Market research confirmed that Iovance is the only available supplier on the relevant Federal Supply Schedule, and the VA noted its intention to continue monitoring for emerging competitors and alternative therapies in future acquisitions.

Notice text

See attached Limited Sources Justification for the Federal Supply Schedule Order 36F79724D0206 36C24826N0268. Awarded contract 36F79724D0206 to IOVANCE BIOTHERAPEUTICS MANUFACTURING LLC for 393365.83000000 on 2026-01-05.

Files

On GovTribe

Work this opportunity

  • Track it in your pipeline
  • Find teaming partners
  • Similar opportunities
  • Ask GovTribe AI about this opportunity